Pancreatic Cancer Research

ResearcherUniversity Hospitals of ClevelandActive in the last 2 years

Kavin Sugumar

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4311-1312; OpenAlex author ID A5088087894. Sources: OpenAlex.

Their work

Papers
13 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
18
Papers, trials and grants by year

2021: 6 papers · 2022: 4 papers · 2023: 2 papers · 2024: none · 2025: 1 paper

Papers 13

  1. Exceptional responders to immunotherapy in pancreatic cancer: A multi-institutional case series of a rare occurrence. Co-author DOI 10.18632/oncotarget.28739↗
  2. An analysis of time to treatment in patients with pancreatic adenocarcinoma. Co-author DOI 10.1016/j.surg.2023.03.011↗
  3. Trends in and Prognostic Significance of Time to Treatment in Pancreatic Cancer: A Population-Based Study. Co-author DOI 10.1245/s10434-023-14221-9↗
  4. Weight loss during neoadjuvant therapy for pancreatic cancer does not predict poor outcomes. Co-author DOI 10.1016/j.amjsurg.2021.10.001↗
  5. Combined multiagent chemotherapy and radiotherapy is associated with prolonged overall survival in patients with non-operatively managed stage II-III pancreati… Co-author DOI 10.1016/j.hpb.2021.08.938↗
  6. Multimodal therapy with or without irreversible electroporation for unresectable locally advanced pancreatic adenocarcinoma: a systematic review and meta-analy… Co-author DOI 10.1016/j.hpb.2021.12.014↗
  7. Time to Neoadjuvant Chemotherapy Initiation Is not Associated With Survival in Pancreatic Cancer. First author DOI 10.1016/j.jss.2022.03.013↗
  8. The importance of time-to-adjuvant treatment on survival with pancreatic cancer: A systematic review and meta-analysis. Co-author DOI 10.1002/cnr2.1390↗
  9. Neoadjuvant chemoradiation may be associated with improved pathologic response in pancreatic cancer. First author DOI 10.1016/j.amjsurg.2020.11.035↗
  10. Facility volume-survival relationship in patients with early-stage pancreatic adenocarcinoma treated with neoadjuvant chemotherapy followed by pancreatoduodene… First author DOI 10.1016/j.surg.2020.12.003↗
  11. Immunotherapy Is Associated with a Survival Benefit in Patients Receiving Chemotherapy for Metastatic Pancreatic Cancer. Co-author DOI 10.1089/pancan.2021.0003↗
  12. Neoadjuvant Radiotherapy is Associated With Improved Pathologic Outcomes and Survival in Resected Stage II-III Pancreatic Adenocarcinoma Treated With Multiagen… Co-author DOI 10.1177/00031348211038581↗
  13. Elucidating the Causes of Improved Survival in Clinical Trials of Randomized Adjuvant Pancreatic Ductal Adenocarcinoma (PDAC). Co-author DOI 10.1245/s10434-020-08859-y↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jordan Michael Winter · 13 shared papers, 2021–2025 · strength 2.03
  2. Jonathan J. Hue · 12 shared papers, 2021–2025 · strength 1.88
  3. John Brian Ammori · 12 shared papers, 2021–2023 · strength 1.82
  4. Jeffrey M. Hardacre · 12 shared papers, 2021–2023 · strength 1.82
  5. Luke Daniel Rothermel · 10 shared papers, 2021–2023 · strength 1.51
  6. Lee Mayer Ocuin · 10 shared papers, 2021–2023 · strength 1.51
  7. Sarah Coseo Markt · 3 shared papers, 2021–2022 · strength 0.42
  8. Shreya Gupta · 2 shared papers, 2023 · strength 0.36
  9. Andre Alabd · 2 shared papers, 2021–2025 · strength 0.36
  10. Mohamedraed Elshami · 2 shared papers, 2022–2023 · strength 0.35
  11. Jennifer Anne Dorth · 2 shared papers, 2021–2022 · strength 0.26
  12. David Lawrence Bajor · 2 shared papers, 2021–2022 · strength 0.26
  13. Zev A. Wainberg · 1 shared paper, 2025 · strength 0.21
  14. Ashwin Reddy Sama · 1 shared paper, 2025 · strength 0.21
  15. Jason Scott Starr · 1 shared paper, 2025 · strength 0.21
  16. Anup Kasi · 1 shared paper, 2025 · strength 0.21
  17. Hedy Lee Kindler · 1 shared paper, 2025 · strength 0.21
  18. Lei Zheng · 1 shared paper, 2025 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.